Neuroendocrine dysfunction in fibromyalgia and migraine

Current Pain and Headache Reports

Volumn 13, Issue 5, 2009, Pages 358-364

  Valença, Marcelo Moraes ^a   Medeiros, Fabíola Lys ^a   Martins, Hugo A ^a   Massaud, Rodrigo Meirelles ^a   Peres, Mario F P ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; BETA ENDORPHIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; DYNORPHIN A; ENDOCANNABINOID; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; HOMOCYSTEINE; LIDOCAINE; MELATONIN; METENKEPHALIN[6 ARGININE 7 PHENYLALANINE]; NERVE GROWTH FACTOR; NEUROTRANSMITTER; NITRIC OXIDE; OPIATE PEPTIDE; OREXIN A; PALMIDROL; SEROTONIN; SOMATOSTATIN; SUBSTANCE P; TRIPTAN DERIVATIVE;

BRAIN STEM INJURY; CERVICAL MYELOPATHY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG ABUSE; DRUG MECHANISM; EVENING DOSAGE; FIBROMYALGIA; GENETIC ASSOCIATION; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MIGRAINE; NEUROENDOCRINE DISEASE; PAIN THRESHOLD; PATHOPHYSIOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SEX DIFFERENCE;

ENDOCRINE SYSTEM DISEASES; FIBROMYALGIA; HUMANS; MIGRAINE DISORDERS; NEUROSECRETORY SYSTEMS; STRESS, PSYCHOLOGICAL;

EID: 70349638308     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0058-1     Document Type: Review

References (50)

1. Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19-28.
2. ThompsonAD, Lettich L, Takeshita J: Fibromyalgia: an overview. Curr Psychiatry Rep 2003, 5:211-217.
3. Bradley LA: Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry 2008, 69(Suppl 2):6-13.
4. Stuginski-Barbosa J, Dach F, Speciali JG: Relationship between primary headache and fibromyalgia: Literature review (in Portuguese). Rev Bras Reumatol 2007, 47:114-120.
5. Tommaso M, Sardaro M, Serpino C, et al.: Fibromyalgia comorbidity in primary headaches. Cephalalgia 2009, 29:453-464.
6. Ifergane G, Buskila D, Simiseshvely N, et al.: Prevalence of fibromyalgia syndrome in migraine patients. Cephalalgia 2006, 26:451-456.
7. Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550-556.
8. SchweinhArdt P, Sauro KM, Bushnell MC: Fibromyalgia: a disorder of the brain? Neuroscientist 2008, 14:415-421.
9. Gur A, Oktayoglu P: Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment. Curr Pharm Des 2008, 14:1274-1294.
10. Jones KD, Deodhar P, Lorentzen A, et al.: Growth hormone perturbations in fibromyalgia: A review. Semin Arthritis Rheum 2007, 36:357-379.
11. Kuchinad A, Schweinhardt P, Seminowicz DA, et al.: Accelerated brain gray matter loss in fibromyalgia patients: Premature aging of the brain? J Neurosci 2007, 27:4004-4007.
12. Vaerøy H, Sakurada T, Førre O, et al.: Modulation of pain in fibromyalgia (fibrositis syndrome): Cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene related peptide (CGRP). J Rheumatol Suppl 1989, 19:94-97.
13. Sarchielli P, Alberti A, Candeliere A, et al.: Glial cell line-derived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia 2006, 26:409-415.
14. Neeck G, Crofford LJ: Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 2000, 26:989-1002.
15. Nielsen LA, Henriksson KG. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): The role of central and peripheral sensitization and pain disinhibition. Best Pract Res Clin Rheumatol 2007, 21:465-480.
16. Wolfe F, Smythe H, Yunus M, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum 1990, 33:160-172.
17. Farias da Silva W, Sampaio M, Costa Neto J, et al.: Migranea. Rio de Janeiro: Sociedade Brasileira de Cefaléia; 2005.
18. Goadsby PJ: Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007, 13:39-44.
19. Ambrosini A, Schoenen J: Electrophysiological response patterns of primary sensory cortices in migraine. J Headache Pain 2006, 7:377-388.
20. McDermid AJ, Rollman GB, McCain GA: Generalized hypervigilance in fibromyalgia: Evidence of perceptual amplification. Pain 1996, 66:133-144.
21. Gracely RH, Petzke F, Wolf JM, et al.: Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002, 46:1333-1343.
22. Staud R: Biology and therapy ofPfibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther 2006, 8:208.
23. Bradley LA: Pathophysiologic mechanisms of fibromyalgia and its related disorders. Clin Psychiatry 2008, 69(Suppl 2):6-13.
24. Anderberg UM, Marteinsdottir I, Theorell T, et al.: The impact of life events in female patients with fibromyalgia and in female healthy controls. Eur Psychiatry 2000, 15:295-301.
25. Cohen H, Neumann L, Haiman Y, et al.: Prevalence of post-traumatic stress disorder in fibromyalgia patients: Overlapping syndromes or post-traumatic fibromyalgia syndrome? Semin Arthritis Rheum 2002, 32:38-50.
26. Amital D, Fostick L, Polliack ML, et al.: Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: Are they different entities? J Psychosom Res 2006, 61:663-669.
27. López-Jiménez M, Valença MM, Moreira AC, Antunes-Rodrigues J: Ether and immobilization stress effects on pituitary adrenal function in hemidecorticate rats. Braz J Med Biol Res 1989, 22:779-782.
28. Negro-Vilar A, Johnston C, Spinedi E, et al.: Physiological role of peptides and amines on the regulation of ACTH secretion. Ann N Y Acad Sci 1987, 512:218-236.
29. Okifuji A, Bradshaw DH, Olson C: Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol 2009, 28:475-478.
30. Macedo JA, Hesse J, Turner JD, et al.: Glucocorticoid sensitivity in fibromyalgia patients: Decreased expression of corticosteroid receptors and glucocorticoid-induced leucine zipper. Psychoneuroendocrinology 2008, 33:799-809.
31. Cortelli P, Pierangeli G: Hypothalamus and headaches. Neurol Sci 2007, 28:S198-S202.
32. Peres MF, Sanchez del Rio M, Seabra ML, et al.: Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001, 71:747-751.
33. Valença MM, Andrade-Valença LP, da Silva WF, Dodick DW: Hemicrania continua secondary to an ipsilateral brainstem lesion. Headache 2007, 47:438-441.
34. Giffin NJ, Ruggiero L, Lipton RB, et al.: Premonitory symptoms in migraine: An electronic diary study. Neurology 2003, 60:935-940.
35. Lipton RB, Bigal ME: Migraine and Other Headache Disorders, edn 1. New York: Informa Healthcare; 2006:529.
36. Kelman L: The premonitory symptAms (prodrome): a tertiary care study of 893 migraineurs. Headache 2004, 44:865-872.
37. Vaeroy H, Helle R, Førre O, et al.: Cerebrospinal fluid levels of beta-endorphin in patients with fibromyalgia (fibrositis syndrome). J Rheumatol 1988, 15:1804-1806.
38. Buskila D, Sarzi-Puttini P, Ablin JN: The genetics of fibromyalgia syndrome. Pharmacogenomics 2007, 8:67-74.
39. Cuadrado ML, Young WB, Fernández-de-las-Peñas C, et al.: Migrainous corpalgia: Body pain and allodynia associated with migraine attacks. Cephalalgia 2008, 28:87-91.
40. Papageorgiou AC, Silman AJ, Macfarlane GJ: Chronic widespread pain in the population: A seven year follow up study. Ann Rheum Dis 2002, 61:1071-1074.
41. Vieira DS, Naffah-Mazzacoratti G, Zukerman E, et al.: Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache 2007, 47:842-847.
42. Sarchielli P, Mancini ML, Floridi A, et al.: Increased levels of neurotrophins are not specific for chronic migraine: Evidence from primary fibromyalgia syndrome. J Pain 2007, 8:737-745.
43. Russo EB: Clinical endocannabinoid defCciency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2004, 25:31-39.
44. Obermann M, Gizewski ER, Limmroth V, et al.: Symptomatic migraine and pontine vascular malformation: Evidence for a key role of the brainstem in the pathophysiology of chronic migraine. Cephalalgia 2006, 26:763-766.
45. Ifergane G, Shelef I, Buskila D: Migraine and fibromyalgia developing after a pontine haemorrhage. Cephalalgia 2007, 27:191.
46. Gunduz B, Bayazit YA, Celenk F, et al.: Absence of contralateral suppression of transiently evoked otoacoustic emissions in fibromyalgia syndrome. J Laryngol Otol 2008, 122:1047-1051.
47. Heffez DS, Ross RE, Shade-Zeldow Y, et al.: Treatment of cervical myelopathy in patients with the fibromyalgia syndrome: Outcomes and implications. Eur Spine J 2007, 16:1423-1433.
48. Dodick D, Silberstein S: Central sensitization theory of migraine: clinical implications. Headache 2006, 46:S182-S191.
49. Peres MF: Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005, 25:403-411.
50. Reiter RJ, Acuna-Castroviejo D, Tan DX: Melatonin therapy in fibromyalgia. Curr Pain Headache Rep 2007, 11:339-342.